^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) + Z-endoxifen (Selective estrogen receptor modulator, Selective estrogen receptor α inhibitor, PKCβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes
Published date:
10/11/2021
Excerpt:
Cytotoxicity studies on monolayer cell cultures exhibited that END-DOX-HRPs were three times more toxic to ER+ MCF7 cells than DOX-HRPs and free DOX in hypoxia....The newly designed endoxifen-conjugated, hypoxia-responsive polymersomes might have translational potential for ER+ breast cancer treatment.
DOI:
10.1021/acsomega.1c02250
